Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. (2021)

First Author: Fennell DA

Attributed to: Leicester – Confidence in Concept 2019 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(21)00471-x

PubMed Identifier: 34656227

Publication URI: http://europepmc.org/abstract/MED/34656227

Type: Journal Article/Review

Volume: 22

Parent Publication: The Lancet. Oncology

Issue: 11

ISSN: 1470-2045